The funding goes to 28 global organizations and establishes two new networks to address pathogenic threats.
Tumors in younger individuals exhibited a dysregulated molecular aging phenotype and were associated with hallmarks of premature senescence.
A team led by researchers at the University of Cambridge analyzed more than 160 pre-treatment tumor biopsies to identify features linked to treatment response.
Cytena will supply nearly 100 of its single-cell isolators, including its Up Sight instrument, to China's Applitech Pharmaceutical Equipment Technology for distribution.
An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.
The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.
People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.
In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
The risk loci highlight shared ties and differences between ALS and other neurodegenerative conditions, and further suggested a role for autophagy in ALS development.
According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.
A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.
Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.
In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.
The pharma firm is using Caris’ comprehensive molecular profiling to help advance its investigational Porcupine inhibitor, RXC004, in the US.
Last week, GenomeWeb's readers were most interested in a jury's decision that BGI and its affiliates were responsible for patent infringement against Illumina.
The firm said it will use the funds to further its commercial infrastructure and application development as it targets a Q1 2022 launch for its proteomics platform.
The agency's bioinformatics analysis suggests 26 assays from 23 developers are likely to be impacted by mutations present in the Omicron variant.
News items for the week of Nov. 29, 2021.
In a cohort of almost 36,000 Icelanders, the researchers found more than 18,000 associations between sequence variants and plasma protein levels.